Minimizing cardiac risks with contemporary radiation therapy for Hodgkin lymphoma

Journal of Clinical Oncology

Volumn 34, Issue 3, 2016, Pages 208-210

  Maraldo, Maja V ^a   Ng, Andrea K ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMPUTER ASSISTED RADIOTHERAPY; EDITORIAL; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION DOSE REDUCTION; RADIATION EXPOSURE; RISK REDUCTION; TREATMENT INDICATION; TREATMENT PLANNING; CORONARY DISEASE; FEMALE; HEART; MALE; RADIATION INJURIES; RADIATION RESPONSE;

CORONARY DISEASE; FEMALE; HEART; HODGKIN DISEASE; HUMANS; MALE; RADIATION INJURIES;

EID: 84955506016     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.6588     Document Type: Editorial

References (41)

1. Dollinger MR, Lavine DM, Foye LV, Jr: Myocardial infarction due to post-irradiation fibrosis of the coronary arteries. Case of successfully treated Hodgkin's disease with lower esophageal involvement. JAMA 195:316-319, 1966
2. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955, 1993
3. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208-1215, 1993
4. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606, 2009
5. Schellong G, Riepenhausen M, Bruch C, et al: Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55:1145-1152, 2010
6. Tukenova M, Guibout C, Oberlin O, et al: Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28:1308-1315, 2010
7. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013
8. van Nimwegen FA, Schaapveld M, Cutter DJ, et al: Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34:235-243, 2016
9. van Nimwegen FA, Cutter DJ, Schaapveld M, et al: Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation x-rays. Int J Radiat Oncol Biol Phys 92:153-160, 2015
10. Olszewski AJ, Shrestha R, Castillo JJ: Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: Analysis of the National Cancer Data Base. J Clin Oncol 33:625-633, 2015
11. Parikh RR, Grossbard ML, Harrison LB, et al: Early-stage classic Hodgkin lymphoma: The utilization of radiation therapy and its impact on overall survival. Int J Radiat Oncol Biol Phys 93:684-693, 2015
12. Raemaekers JM, André MP, Federico M, et al: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188-1194, 2014
13. Meyer RM, Gospodarowicz MK, Connors JM, et al: NCIC Clinical Trials Group; Eastern Cooperative Oncology Group: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366:399-408, 2012
14. Radford J, Illidge T, Counsell N, et al: Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 372:1598-1607, 2015
15. Longo DL, Armitage JO: Controversies in the treatment of early-stage Hodgkin's lymphoma. N Engl J Med 372:1667-1669, 2015
16. Chera BS, Rodriguez C, Morris CG, et al: Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: Conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 75:1173-1180, 2009
17. Campbell BA, Hornby C, Cunninghame J, et al: Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 23:1259-1266, 2012
18. Fiandra C, Filippi AR, Catuzzo P, et al: Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: Dosimetric comparison and clinical considerations. Radiat Oncol 7:186, 2012
19. Aznar MC, Maraldo MV, Schut DA, et al: Minimizing late effects for patients with mediastinal Hodgkin lymphoma: Deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys 92:169-174, 2015
20. Paumier A, Ghalibafian M, Beaudre A, et al: Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80:199-205, 2011
21. Petersen PM, Aznar MC, Berthelsen AK, et al: Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold. Acta Oncol 54:60-66, 2015
22. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
23. Eich HT, Diehl V, Görgen H, et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199-4206, 2010
24. Torok JA, Wu Y, Prosnitz LR, et al: Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92:54-59, 2015
25. Hull MC, Morris CG, Pepine CJ, et al: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 290:2831-2837, 2003
26. Maraldo MV, Brodin NP, Vogelius IR, et al: Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83:1232-1237, 2012
27. Maraldo MV, Brodin NP, Aznar MC, et al: Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 24:2113-2118, 2013
28. Koeck J, Abo-Madyan Y, Lohr F, et al: Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): The roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys 83:268-276, 2012
29. Antoni D, Natarajan-Ame S, Meyer P, et al: Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease. Radiat Oncol 8:112, 2013
30. Dabaja BS, Rebueno NC, Mazloom A, et al: Radiation for Hodgkin's lymphoma in young female patients: A new technique to avoid the breasts and decrease the dose to the heart. Int J Radiat Oncol Biol Phys 79:503-507, 2011
31. Girinsky T, Pichenot C, Beaudre A, et al: Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 64:218-226, 2006
32. Goodman KA, Toner S, Hunt M, et al: Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62:198-206, 2005
33. De Sanctis V, Bolzan C, D'Arienzo M, et al: Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy? Radiat Oncol 7:129, 2012
34. Maraldo MV, Specht L: A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: What can we learn? Int J Radiat Oncol Biol Phys 90:1126-1135, 2014
35. Hoppe BS, Flampouri S, Su Z, et al: Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: Preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys 83:260-267, 2012
36. Hoppe BS, Flampouri S, Su Z, et al: Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 84:449-455, 2012
37. Hoppe BS, Flampouri S, Zaiden R, et al: Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: Results of a phase 2 study. Int J Radiat Oncol Biol Phys 89:1053-1059, 2014
38. Paumier A, Ghalibafian M, Gilmore J, et al: Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 82:1522-1527, 2012
39. Charpentier AM, Conrad T, Sykes J, et al: Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol 4:174-180, 2014
40. NCCN Clinical Practice Guidelines in Oncology: Hodgkin lymphoma. http://www.nccn.org/professionals/physician-gls/PDF/hodgkins.pdf
41. Straus DJ, Portlock CS, Qin J, et al: Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483-3489, 2004